Rocket Pharmaceuticals to Present at Upcoming Investor Conferences
29 March 2022 - 10:00PM
Business Wire
Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a clinical-stage
company advancing an integrated and sustainable pipeline of genetic
therapies for rare childhood disorders, today announces that
Kinnari Patel, Pharm.D., MBA, President and Chief Operating
Officer, will deliver a virtual company presentation at the
Guggenheim 3rd Annual Genomic Medicines and Rare Disease Conference
on Friday, April 1 at 8:00 a.m. ET. Gaurav Shah, M.D., Chief
Executive Officer, will present at the 21st Annual Needham Virtual
Healthcare Conference on Monday, April 11 at 10:15 a.m. ET.
A live audio webcast of the presentations will be available
under “Events” in the Investors section of the Company’s website at
https://ir.rocketpharma.com. The webcast replay will be available
on the Rocket website following the conferences.
About Rocket Pharmaceuticals, Inc.
Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) is advancing an
integrated and sustainable pipeline of genetic therapies that
correct the root cause of complex and rare childhood disorders. The
Company’s platform-agnostic approach enables it to design the best
therapy for each indication, creating potentially transformative
options for patients afflicted with rare genetic diseases. Rocket's
clinical programs using lentiviral vector (LVV)-based gene therapy
are for the treatment of Fanconi Anemia (FA), a difficult to treat
genetic disease that leads to bone marrow failure and potentially
cancer, Leukocyte Adhesion Deficiency-I (LAD-I), a severe pediatric
genetic disorder that causes recurrent and life-threatening
infections which are frequently fatal, Pyruvate Kinase Deficiency
(PKD), a rare, monogenic red blood cell disorder resulting in
increased red cell destruction and mild to life-threatening anemia,
and Infantile Malignant Osteopetrosis (IMO), a bone marrow-derived
disorder. Rocket’s first clinical program using adeno-associated
virus (AAV)-based gene therapy is for Danon Disease, a devastating,
pediatric heart failure condition. For more information about
Rocket, please visit www.rocketpharma.com.
Rocket Cautionary Statement Regarding Forward-Looking
Statements
Various statements in this release concerning Rocket’s future
expectations, plans and prospects, including without limitation,
Rocket’s expectations regarding its guidance for 2022 in light of
COVID-19, the safety and effectiveness of product candidates that
Rocket is developing to treat Fanconi Anemia (FA), Leukocyte
Adhesion Deficiency-I (LAD-I), Pyruvate Kinase Deficiency (PKD),
and Danon Disease, the expected timing and data readouts of
Rocket’s ongoing and planned clinical trials, Rocket’s plans for
the advancement of its Danon Disease program following the lifting
of the FDA’s clinical hold and the safety, effectiveness and timing
of related pre-clinical studies and clinical trials, may constitute
forward-looking statements for the purposes of the safe harbor
provisions under the Private Securities Litigation Reform Act of
1995 and other federal securities laws and are subject to
substantial risks, uncertainties and assumptions. You should not
place reliance on these forward-looking statements, which often
include words such as "believe," "expect," "anticipate," "intend,"
"plan," "will give," "estimate," "seek," "will," "may," "suggest"
or similar terms, variations of such terms or the negative of those
terms. Although Rocket believes that the expectations reflected in
the forward-looking statements are reasonable, Rocket cannot
guarantee such outcomes. Actual results may differ materially from
those indicated by these forward-looking statements as a result of
various important factors, including, without limitation, Rocket’s
ability to monitor the impact of COVID-19 on its business
operations and take steps to ensure the safety of patients,
families and employees, the interest from patients and families for
participation in each of Rocket’s ongoing trials, our expectations
regarding the delays and impact of COVID-19 on clinical sites,
patient enrollment, trial timelines and data readouts, our
expectations regarding our drug supply for our ongoing and
anticipated trials, actions of regulatory agencies, which may
affect the initiation, timing and progress of pre-clinical studies
and clinical trials of its product candidates, Rocket’s dependence
on third parties for development, manufacture, marketing, sales and
distribution of product candidates, the outcome of litigation, and
unexpected expenditures, as well as those risks more fully
discussed in the section entitled "Risk Factors" in Rocket’s
Quarterly Report on Form 10-Q for the quarter ended September 30,
2021, filed November 5, 2021 with the SEC. Accordingly, you should
not place undue reliance on these forward-looking statements. All
such statements speak only as of the date made, and Rocket
undertakes no obligation to update or revise publicly any
forward-looking statements, whether as a result of new information,
future events or otherwise.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220329005276/en/
Media Kevin Giordano Director, Corporate Communications
kgiordano@rocketpharma.com
Investors Jessie Yeung, M.B.A. Vice President, Investor
Relations and Corporate Finance investors@rocketpharma.com
Rocket Pharmaceuticals (NASDAQ:RCKT)
Historical Stock Chart
From Apr 2024 to May 2024
Rocket Pharmaceuticals (NASDAQ:RCKT)
Historical Stock Chart
From May 2023 to May 2024